{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:38:47Z","timestamp":1768750727925,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.brachy.2020.07.011","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T18:06:15Z","timestamp":1597773975000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-2979","authenticated-orcid":false,"given":"Georgios","family":"Chatzikonstantinou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Scherf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-1953","authenticated-orcid":false,"given":"Bastian","family":"Bathen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janett","family":"K\u00f6hn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Tselis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2020.07.011_bib1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.brachy.2020.07.011_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.07.011_bib3","doi-asserted-by":"crossref","first-page":"S632","DOI":"10.21037\/tcr.2018.01.30","article-title":"Hypofractionation in prostate cancer radiotherapy","volume":"7","author":"Brenner","year":"2018","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.brachy.2020.07.011_bib4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.07.011_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-Year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2020.07.011_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.adro.2019.09.010","article-title":"Gantry-mounted linear accelerator\u2013based stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"5","author":"Dang","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/153303460300200104","article-title":"CyberKnife radiotherapy for localized prostate cancer: Rationale and technical feasibility","volume":"2","author":"King","year":"2003","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.brachy.2020.07.011_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2017.02.015","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer: Review of the current status","volume":"29","author":"Tselis","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib9","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ijrobp.2007.11.067","article-title":"Virtual HDR CyberKnife treatment for localized prostatic carcinoma: Dosimetry comparison with HDR brachytherapy and preliminary clinical observations","volume":"70","author":"Fuller","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.07.011_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.brachy.2013.03.003","article-title":"A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer","volume":"12","author":"Spratt","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2020.07.011_bib11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/jrr\/rru048","article-title":"Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife","volume":"55","author":"Fukuda","year":"2014","journal-title":"J Radiat Res"},{"key":"10.1016\/j.brachy.2020.07.011_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.radonc.2016.05.008","article-title":"Real-time in\u00a0vivo dosimetry in high dose rate prostate brachytherapy","volume":"120","author":"Mason","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2013.11.002","article-title":"Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM","volume":"110","author":"Kirisits","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13014-017-0872-2","article-title":"Hypo-fractionated SBRT for localized prostate cancer: A German bi-center single treatment group feasibility trial","volume":"12","author":"Jiang","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fonc.2011.00048","article-title":"Six-dimensional correction of intra-fractional prostate motion with CyberKnife stereotactic body radiation therapy","volume":"1","author":"Lei","year":"2011","journal-title":"Front Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2017.09.038","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer","volume":"126","author":"Strouthos","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0360-3016(03)00747-8","article-title":"The low alpha\/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?","volume":"57","author":"Wang","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.07.011_bib18","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2012.07.004","article-title":"High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: Treatment evolution and mature results","volume":"85","author":"Zamboglou","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.07.011_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.semradonc.2017.02.006","article-title":"Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer","volume":"27","author":"Kishan","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib20","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1118\/1.3618735","article-title":"4D analysis of influence of patient movement and anatomy alteration on the quality of 3D U\/S-based prostate HDR brachytherapy treatment delivery","volume":"38","author":"Milickovic","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.brachy.2020.07.011_bib21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2020.07.011_bib22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3109\/0284186X.2010.486796","article-title":"Severe hypofractionation: Non-homogeneous tumour dose delivery can counteract tumour hypoxia","volume":"49","author":"Ruggieri","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.brachy.2020.07.011_bib23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2020.07.011_bib24","doi-asserted-by":"crossref","first-page":"pkaa006","DOI":"10.1093\/jncics\/pkaa006","article-title":"Comparative effectiveness of different radical radiotherapy treatment regimens for prostate cancer: A population-based cohort study","volume":"4","author":"Pettersson","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.brachy.2020.07.011_bib25","first-page":"690","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"14","author":"Morton","year":"2020","journal-title":"Radiother Oncol"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472120301483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472120301483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:17:08Z","timestamp":1761531428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472120301483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1538472120301483"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2020.07.011","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2020.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}